CONKO-001: FINAL RESULTS OF THE RANDOMIZED, PROSPECTIVE, MULTICENTER PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY WITH GEMCITABINE VERSUS OBSERVATION IN PATIENTS WITH RESECTED PANCREATIC CANCER (PC)

被引：0
|
作者：
Riess, H.
Neuhaus, P.
Post, S.
Gellert, K.
Ridwelski, K.
Schramm, H.
Zuelke, C.
Fahlke, J.
Langrehr, J.
Oettle, H.
机构：
来源：
ANNALS OF ONCOLOGY | 2008年 / 19卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：45 / 46
页数：2
相关论文
共 50 条
  • [21] ESPAC-4: A Multicenter, International, Randomized Controlled Phase III Trial of Adjuvant Combination Chemotherapy of Gemcitabine (GEM) and Capecitabine (CAP), Versus Monotherapy Gemcitabine in Patients With Resected Pancreatic Ductal Adenocarcinoma
    Neoptolemos, J. P.
    Palmer, D.
    Ghaneh, P.
    Valle, J.
    Cunningham, D.
    Wadsley, J.
    Meyer, T.
    Anthoney, A.
    Glimelius, B.
    Falk, S.
    Lind, P.
    Izbicki, J.
    Middleton, G.
    Ross, P.
    Wasan, H.
    McDonald, A.
    Crosby, T.
    Psarelli, E.
    Hammel, P.
    Buechler, M. W.
    PANCREAS, 2016, 45 (10) : 1529 - 1529
  • [22] TP53 Mutations Predict Sensitivity to Adjuvant Gemcitabine in Patients with Pancreatic Ductal Adenocarcinoma: Next-Generation Sequencing Results from the CONKO-001 Trial
    Sinn, Marianne
    Sinn, Bruno, V
    Treue, Denise
    Keilholz, Ulrich
    Damm, Frederik
    Schmuck, Rosa
    Lohneis, Philipp
    Klauschen, Frederick
    Striefler, Jana K.
    Bahra, Marcus
    Blaeker, Hendrik
    Bischoff, Sven
    Pelzer, Uwe
    Oettle, Helmut
    Riess, Hanno
    Budczies, Jan
    Denkert, Carsten
    CLINICAL CANCER RESEARCH, 2020, 26 (14) : 3732 - 3739
  • [23] Randomized multicenter phase II/III study with adjuvant gemcitabine versus neoadjuvant/adjuvant FOLFIRINOX in resectable pancreatic cancer: The NEPAFOX trial.
    Hozaeel, Wael
    Pauligk, Claudia
    Homann, Nils
    Luley, Kim
    Kraus, Thomas Werner
    Trojan, Jorg
    Bechstein, Wolf O.
    Grimm, Kersten
    Heise, Bettina
    Schmiegel, Wolff
    Pink, Daniel
    Al-Batran, Salah-Eddin
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [24] Randomized multicenter phase II/III study with adjuvant gemcitabine versus neoadjuvant/adjuvant FOLFIRINOX in resectable pancreatic cancer: The NEPAFOX trial.
    Al-Batran, Salah-Eddin
    Reichart, Alexander
    Bankstahl, Ulli Simone
    Pauligk, Claudia
    Kraus, Thomas Werner
    Bechstein, Wolf Otto
    Trojan, Jorg
    Behrend, Matthias
    Potenberg, Jochem
    Homann, Nils
    Venerito, Marino
    Bohle, Wolfram
    Varvenne, Michael
    Bolling, Claus
    Behringer, Dirk M.
    Kratz-Alber, Karsten
    Siegler, Gabriele Margareta
    Hozaeel, Wael
    Goetze, Thorsten Oliver
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [25] Adjuvant chemotherapy with gemcitabine plus erlotinib vs. gemcitabine alone for patients with resected pancreatic ductal adenocarcinoma: is there a role for erlotinib?-review of the open label phase III trial CONKO 005
    Wisniewski, Mathilde
    Placide, Pierre-Alain
    Granier, Sandra
    Al Shatti, Yacoub
    Al Qalaf, Shuaib
    Bouattour, Mohamed
    Lamuraglia, Michele
    Hammel, Pascal
    HEPATOBILIARY SURGERY AND NUTRITION, 2018, 7 (05) : 399 - 402
  • [26] Adjuvant Gemcitabine Versus Neoadjuvant/Adjuvant FOLFIRINOX in Resectable Pancreatic Cancer: The Randomized Multicenter Phase II NEPAFOX Trial
    Goetze, Thorsten O.
    Reichart, Alexander
    Bankstahl, Ulli S.
    Pauligk, Claudia
    Loose, Maria
    Kraus, Thomas W.
    Elshafei, Moustafa
    Bechstein, Wolf O.
    Trojan, Joerg
    Behrend, Matthias
    Homann, Nils
    Venerito, Marino
    Bohle, Wolfram
    Varvenne, Michael
    Bolling, Claus
    Behringer, Dirk M.
    Kratz-Albers, Karsten
    Siegler, Gabriele M.
    Hozaeel, Wael
    Al-Batran, Salah-Eddin
    ANNALS OF SURGICAL ONCOLOGY, 2024, 31 (06) : 4073 - 4083
  • [27] Adjuvant Gemcitabine Versus Neoadjuvant/Adjuvant FOLFIRINOX in Resectable Pancreatic Cancer: The Randomized Multicenter Phase II NEPAFOX Trial
    Thorsten O. Goetze
    Alexander Reichart
    Ulli S. Bankstahl
    Claudia Pauligk
    Maria Loose
    Thomas W. Kraus
    Moustafa Elshafei
    Wolf O. Bechstein
    Jörg Trojan
    Matthias Behrend
    Nils Homann
    Marino Venerito
    Wolfram Bohle
    Michael Varvenne
    Claus Bolling
    Dirk M. Behringer
    Karsten Kratz-Albers
    Gabriele M. Siegler
    Wael Hozaeel
    Salah-Eddin Al-Batran
    Annals of Surgical Oncology, 2024, 31 : 4073 - 4083
  • [28] Adjuvant gemcitabine versus NEOadjuvant gemcitabine/oxaliplatin plus adjuvant gemcitabine in resectable pancreatic cancer: a randomized multicenter phase III study (NEOPAC study)
    Heinrich, Stefan
    Pestalozzi, Bernhard
    Lesurtel, Mickael
    Berrevoet, Frederik
    Laurent, Stephanie
    Delpero, Jean-Robert
    Raoul, Jean-Luc
    Bachellier, Phillippe
    Dufour, Patrick
    Moehler, Markus
    Weber, Achim
    Lang, Hauke
    Rogiers, Xavier
    Clavien, Pierre-Alain
    BMC CANCER, 2011, 11
  • [29] A randomized phase II trial of adjuvant chemotherapy with uracil / tegafur (UFT) and gemcitabine (GEM) vs. gemcitabine alone in patients with resected pancreatic cancer
    Yoshitomi, H.
    Togawa, A.
    Kimura, F.
    Shimizu, H.
    Yoshidome, H.
    Miyazaki, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [30] Adjuvant gemcitabine versus NEOadjuvant gemcitabine/oxaliplatin plus adjuvant gemcitabine in resectable pancreatic cancer: a randomized multicenter phase III study (NEOPAC study)
    Stefan Heinrich
    Bernhard Pestalozzi
    Mickael Lesurtel
    Frederik Berrevoet
    Stéphanie Laurent
    Jean-Robert Delpero
    Jean-Luc Raoul
    Phillippe Bachellier
    Patrick Dufour
    Markus Moehler
    Achim Weber
    Hauke Lang
    Xavier Rogiers
    Pierre-Alain Clavien
    BMC Cancer, 11
12345